ACM
IRLA

Anfield Capital Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Anfield Capital Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-471
Closed -$316K – 723
2025
Q4 		$316K Buy
471
+320
+212% +$161K 0.1% 74
2025
Q3 		$49.3K Hold
151
– – 0.01% 187
2025
Q2 		$49.9K Hold
151
– – 0.02% 167
2025
Q1 		$40.2K Buy
151
+18
+14% +$5.5K 0.01% 163
2024
Q4 		$49.8K Buy
+133
New +$39.9K 0.02% 149

Other funds holding IRLA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Anfield Capital Management's IRLA Position: Q1 2026 in Review

Anfield Capital Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2026, closing a stake of 471 shares — an estimated $316K sold.

Anfield Capital Management first reported a position in IRLA in Q4 2024 and held it in 5 quarters. The position peaked at $316K in Q4 2025. 43 funds tracked by Wall St. Rank hold IRLA as of Q1 2026.

  • Anfield Capital Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • Anfield Capital Management sold 471 IRulya Therapeutics Inc. Common Stock shares in Q1 2026, an estimated $316K.
  • Anfield Capital Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2024 and held it in 5 quarters.
  • Anfield Capital Management's IRulya Therapeutics Inc. Common Stock position peaked at $316K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.